These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26792718)

  • 1. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
    Cheng F; Wang L; Shen Y; Xia J; Chen H; Jiang Y; Lu M
    Biochem Biophys Res Commun; 2016 Feb; 470(2):324-330. PubMed ID: 26792718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
    Pan XD; Gu DH; Mao JH; Zhu H; Chen X; Zheng B; Shan Y
    PLoS One; 2017; 12(3):e0172555. PubMed ID: 28257457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
    Xu L; Zhang Y; Gao M; Wang G; Fu Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.
    Zhang D; Xia H; Zhang W; Fang B
    Tumour Biol; 2016 Jan; 37(1):1327-36. PubMed ID: 26293898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
    Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
    Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
    Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
    Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.
    Wang L; Zhu YR; Wang S; Zhao S
    Tumour Biol; 2016 Sep; 37(9):11743-11752. PubMed ID: 27020593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
    Jiang H; Zeng Z
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
    J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
    Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
    Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.
    Jiang SJ; Wang S
    Tumour Biol; 2015 Sep; 36(10):8177-84. PubMed ID: 25990456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
    Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
    Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
    Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
    Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
    Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
    Willems L; Chapuis N; Puissant A; Maciel TT; Green AS; Jacque N; Vignon C; Park S; Guichard S; Herault O; Fricot A; Hermine O; Moura IC; Auberger P; Ifrah N; Dreyfus F; Bonnet D; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Leukemia; 2012 Jun; 26(6):1195-202. PubMed ID: 22143671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
    Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
    Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
    Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
    Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.
    Merhi F; Tang R; Piedfer M; Mathieu J; Bombarda I; Zaher M; Kolb JP; Billard C; Bauvois B
    PLoS One; 2011; 6(10):e25963. PubMed ID: 21998731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
    Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
    Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.